Abstracts tagged "anti-TNF therapy"

Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…
Abstract Number: 2347 • 2013 ACR/ARHP Annual Meeting
Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP3 (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients
Jacob Sode^1,2,3, Niels H. H. Heegaard⁴, Henning Locht², Ulla Vogel⁵, Steffen Bank^6,7, Merete Lund Hetland^8,9 and Vibeke Andersen^3,7,10,11, ¹Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁵National Research Centre for the Working Environment, Copenhagen, Denmark, ⁶Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁷Medical Department, Viborg Regional Hospital, Viborg, Denmark, ⁸The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ¹⁰Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, ¹¹Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Background/Purpose: Most patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-a blocking treatment (anti-TNF). About 1/3, however, do not respond to this costly and…
Abstract Number: 1516 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Jürgen Braun⁴, Walter P. Maksymowych⁵, Gustavo Citera⁶, James Cheng-Chung Wei⁷, Jan Lenaerts⁸, Ronald Pedersen⁹, Randi Bonin¹⁰, Ehab Y. Mahgoub¹⁰, Bonnie Vlahos¹⁰ and Jack Bukowski¹¹, ¹Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁸Reuma Instituut, Hasselt, Belgium, ⁹Specialty Care, Pfizer Inc, Collegeville, PA, ¹⁰Pfizer Inc, Collegeville, PA, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). The objective of this analysis is to compare the…
Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 2322 • 2013 ACR/ARHP Annual Meeting
Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Tsutomu Takeuchi¹, Kazuhiko Yamamoto^2,3, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Mariko Kobayashi¹⁰, Toshiharu Shoji¹⁰, Nobuyuki Miyasaka¹¹ and Takao Koike¹², ¹Department of Rheumatology, Keio University, Tokyo, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Sasebo City General Hospital, Sasebo, Nagasaki, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Tokyo Medical and Dental University, Tokyo, Japan, ¹²Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: Certolizumab pegol (CZP) with MTX (J-RAPID; NCT00791999) and without MTX (HIKARI; NCT00791921) has demonstrated rapid and sustained improvements in disease activity in Japanese patients…
Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Mathieu Verdet¹, Clément Guillou², Julien Michaud¹, Christopher Banse¹, Sandra Desouches¹, Gilles Avenel³, Quentin Bréhier⁴, Aurélia Bisson-Vaivre¹, Sophie Pouplin¹ and Olivier Vittecoq⁵, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Rheumaotlogy, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Le Havre Hospital, Le Havre, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…
Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
B Dasgupta¹, P Bertin², L Settas³, JE Fonseca⁴, V Wolff⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Dupuytren, Limoges, France, ³AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, ⁴Lisbon Academic Medical Centre, Lisboa, Portugal, ⁵Hospital del Salvador, Santiago, Chile, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…
Abstract Number: 2323 • 2013 ACR/ARHP Annual Meeting
Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Tadao Okamoto⁹, Yumiko Wada⁹, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Keio University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, ⁶Sasebo City General Hospital, Sasebo, Japan, ⁷Tohoku University, Sendai, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹UCB Pharma, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive…
Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol
Désirée M. van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Nevsun Inanc^1,2, Gülsen Ozen² and Haner Direskeneli³, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…
Abstract Number: 2237 • 2013 ACR/ARHP Annual Meeting
Assessment Of Wage and Salary Growth In Patients With Rheumatoid Arthritis (RA)
Martin J. Bergman¹, Gourab De², Arijit X. Ganguli³, James Signorovitch⁴ and Yanjun Bao⁵, ¹Taylor Hospital, Ridley Park, PA, ²Analysis Group, Inc., New York, NY, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: RA negatively impacts patients' work outcomes. Treatment with tumor necrosis factor inhibitors (anti-TNFs) has been associated with improved work productivity and stability in RA.…
Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Hubert Marotte¹, Sara Djemouai², Béatrice Pallot-Prades², Hervé Locrelle³ and Thierry Thomas⁴, ¹LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France, ²University Hospital, Saint-Etienne, France, ³INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Kimme L. Hyrich², Mark Lunt³, Louise K. Mercer³, Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Deborah P. Symmons^3,8 and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].